branebrutinib   Click here for help

GtoPdb Ligand ID: 9869

Synonyms: BMS-986195 | BMS986195 | Example 223 [US20160115126A1]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Branebrutinib (BMS-986195) is a potent, covalent, irreversible inhibitor of the TEC family non-receptor tyrosine kinase, Bruton's tyrosine kinase (BTK) [2]. BTK is essential in antigen-dependent B cell signaling and function, and is a therapeutic target for oncology and rheumatic diseases. Branebrutinib is a clinical lead for the treatment of rheumatoid arthritis, as claimed in Bristol-Myers Squibb's patent US20160115126A1 (Example 223) [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 4
Topological polar surface area 91.22
Molecular weight 370.18
XLogP 3.31
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CC#CC(=O)NC1CCCN(C1)c1c(F)cc(c2c1c(C)c([nH]2)C)C(=O)N
Isomeric SMILES CC#CC(=O)N[C@H]1CCCN(C1)c1c(F)cc(c2c1c(C)c([nH]2)C)C(=O)N
InChI InChI=1S/C20H23FN4O2/c1-4-6-16(26)24-13-7-5-8-25(10-13)19-15(21)9-14(20(22)27)18-17(19)11(2)12(3)23-18/h9,13,23H,5,7-8,10H2,1-3H3,(H2,22,27)(H,24,26)/t13-/m0/s1
No information available.
Summary of Clinical Use Click here for help
BMS-986195 has completed Phase 1 trials in healthy subjects but not yet in patients with RA. As of August 2019 there has been no further development of BMS-986195.